G1 Therapeutics, Inc. (G1H.F)
Chart Events
Performance Outlook
| Previous Close | 6.15 |
| Open | 6.80 |
| Bid | 7.01 x 0 |
| Ask | 7.20 x 0 |
| Day's Range | 6.80 - 6.80 |
| 52 Week Range | 3.79 - 16.91 |
| Volume | |
| Avg. Volume | 260 |
| Market Cap | 357.83M |
| Beta (5Y Monthly) | 1.61 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for G1H.F
Related Research
- Benzinga
G1 Therapeutics Reveals An Early Cut Data From Bladder Cancer Trial
G1 Therapeutics Inc (NASDAQ: GTHX) provided an initial update on the PRESERVE 3 Phase 2 study of first-line platinum-based chemotherapy and maintenance therapy with avelumab, administered alone, or in combination with trilaciclib, in patients with untreated, locally advanced or metastatic urothelial carcinoma (mUC). Additional safety and efficacy data, including the primary endpoint of progression-free survival (PFS), are anticipated in the middle of 2023. The confirmed objective response rate (
- American City Business Journals
G1 Therapeutics raises $50M to help lift sales for cancer drug
An oncology company in Research Triangle Park has raised new capital to support sales of its sole product and fund development of new cancer drugs.
- Simply Wall St.
Newsflash: G1 Therapeutics, Inc. (NASDAQ:GTHX) Analysts Have Been Trimming Their Revenue Forecasts
One thing we could say about the analysts on G1 Therapeutics, Inc. ( NASDAQ:GTHX ) - they aren't optimistic, having...
